Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

Circulating tumor DNA (ctDNA) has emerged as a biomarker with wide-ranging applications
in cancer management. While its role in guiding precision medicine in certain tumors via …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …

Technological advancements in research on circulating biomarkers from patient derived
blood have enabled a less invasive means of diagnosing non-hematologic cancers …

Metastasis is a biologically complex process consisting of numerous stochastic events which
may tremendously differ across various cancer types. Circulating tumor cells (CTCs) are …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Cell-free DNA (cfDNA) refers to short fragments of acellular nucleic acids detectable in
almost all body fluids, including blood, and is involved in various physiological and …

In the field of cancer detection, technologies to analyze tumors using biomarkers circulating
in fluids such as blood have developed rapidly based on liquid biopsy. A proactive approach …

The analysis of cell-free DNA (cfDNA) in plasma represents a rapidly advancing field in
medicine. cfDNA consists predominantly of nucleosome-protected DNA shed into the …